



## DAFTAR PUSTAKA

- Ambrogi, V., Pompeo, E., Elia, S., Pistolese, G.R., Mineo, T.C., 2003. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. *European journal of cardio-thoracic surgery*. 23:811–817.
- Andersen, A., Berge, S., Engeland, A., Norseth, T., 1996. Exposure to nickel compounds and smoking in relation to incidence of lung and nasal cancer among nickel refinery workers. *Occup Environ Med*. 53(10):708–713.
- Arnold, B.N., Thomas, D.C., Rosen, J.E. 2016. Lung cancer in the very young: Treatment and survival in the National Cancer Data Base. *J Thorac Oncol*. 11:1121-31.
- Attfield, M.D., Schleiff, P.L., Lubin, J.H., 2012. The diesel exhaust in miners' study: a cohort mortality study with emphasis on lung cancer. *J Natl Cancer Inst*. 104:869–83.
- Bambace, N.M., Holmes, C.E., 2011. The platelet contribution to cancer progression. *J Thromb Haemost*. 9(2):237–249.
- Birk, T., Mundt, K.A., Dell, L.D., Luippold, R.S., et al., 2006. Lung cancer mortality in the German chromate industry, 1958 to 1998. *J Occup Environ Med*. 48(4):426–433.
- Boice, J.D., 1996. Ionizing radiation. In: Schottenfeld, D., Fraumeni, J.J. (Ed): *Cancer Epidemiology and Prevention*, pp: 319–354. Oxford University Press, New York.
- Caires-Lima, R., Cayres, K., Protálio, B., Caires, I., et al., 2018. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. *Ecancermedicalscience*. 12:831.
- Cao, S., Jin, S., Shen, J., Cao, J., et al., 2017. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. *Oncotarget*. 8(5):8657–8669.
- Chen, J.H., Zhai, E.T., Yuan, Y.J., Wu, K.M., et al., 2017. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. *World J Gastroenterol*. 23:6261–6272.
- Chao, D., Zhang, N., Wang, Y., Jiang, S., et al., 2019. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. *Medicine*, 98:33.
- Cetin, K., Ettinger, D.S., Hei, Y.J., O'Malley, C.D., 2011. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. *Clin Epidemiol*. 3:139-148.
- Cote, M.L., Liu, M., Bonassi, S., 2012. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. *Eur J Cancer*. 48: 1957–1968.
- Cuyun-Carter, G., Barrett, A.M., Kaye, J.A., Liepa, A.M., et al., 2014, A



- comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. *Cancer management and research.* 6: 437-449.
- Darby, S., Hill, D., Auvinen, A., 2005. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ.* 330: 223.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., et al., 2014. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 136(5):e359-e386.
- Fu, Y., Chen, S.W., Chen, S.Q., Ou-Yang, D., et al., 2016. A preoperative nutritional index for predicting cancerspecific and overall survival in chinese patients with laryngeal cancer: a retrospective study. *Medicine.* 95(11):e2962.
- Garshick, E., Laden, F., Hart, J.E., 2012. Lung cancer and elemental carbon exposure in trucking industry workers. *Environ Health Perspect.* 120:1301–1306.
- Gomes, M., Teixeira, A.L., Coelho, A., Araújo, A., Medeiros, R., 2014. The role of inflammation in lung cancer. *Adv Exp Med Biol.* 816:1-23.
- Goldstraw, P., Chansky, K., Crowley, J., 2016. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol.* 11(1):39-51.
- Guo, D., Zhang, J., Jing, W., Liu, J., et al., 2018. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. *Future Oncol.* 14:1-8.
- Hammerschmidt, S., & Wirtz, H., 2009. Lung cancer: current diagnosis and treatment. *Deutsches Arzteblatt international.* 106(49), 809–820.
- Hammond, E.C., Selikoff, I.J., Seidman, H., 1979. Asbestos exposure, cigarette smoking and death rates. *Ann N Y Acad Sci.* 330:473-490.
- Herbst, R.S., Heymach, J.V., Lippman, S.M., 2008. Molecular Origins of Lung Cancer. *N Eng J Med.* 359:1367-1380.
- Holgersson, G., 2017. Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC). *Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine* 1359:84 pp. Acta Universitatis Upsaliensis, Uppsala.
- Hong, X., Cui, B., Wang, M., Yang, Z., et al., 2015. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung Cancer. *Tohoku J Exp Med.* 236:297–304.
- Howlader, N., Noone, A.M., Krapcho, M., Miller, D., et al., 2017. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, [https://seer.cancer.gov/csr/1975\\_2014/](https://seer.cancer.gov/csr/1975_2014/), based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
- Hsu, C.L., Chen, J.H., Chen, K.Y., Shih, J.Y., et al., 2015. Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis. *J Geriatr Oncol.* 6: 38–45.



- International Agency for Research on Cancer (IARC), 2012. Arsenic, metals, fibres, and dusts. *IARC Monogr Eval Carcinog Risks Hum.* 100 (Pt C):11-465.
- International Agency for Research on Cancer (IARC), 2012. Internalized alpha-particle emitting radionuclides. *IARC Monogr Eval Carcinog Risks Hum.* 100 (Pt D).
- International Agency for Research on Cancer (IARC), 2013. Diesel and gasoline engine exhausts and some nitroarenes. *IARC Monogr Eval Carcinog Risks Hum.* 105: 9-699.
- Islam, K.M., Jiang, X., Anggondowati, T., Lin, G., Ganti, A.K., 2015. Comorbidity and survival in lung cancer patients. *Cancer Epidemiol Biomarkers Prev.* 24(7):1079–1085.
- Iwasaki, A., Shirakusa, T., Okabayashi, K., Inutsuka, K., et al., 2006. Lung cancer surgery in patients with liver cirrhosis. *Ann Thorac Surg.* 82(3): 1027-1032.
- Iwata, T., Inoue, K., Nishiyama, N., 2007. Long-term outcomes of surgical treatment for non small cell lung cancer with comorbid liver cirrhosis. *Ann Thorac Surg.* 84:1810–7.
- Jafri, S.H., Shi, R., Mills, G., 2013. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. *BMC Cancer.* 13: 158.
- Jemal, A., Travis, W.D., Tarone, R.E., Travis, L. Devesa, S.S. 2003. Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type. *Int J Cancer,* 105:101–7.
- Jin, S., Cao, S., Xu, S., Wang, C., et al., 2018. Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy. *Clin Respir J.* 12(9):2433–2440.
- Jurasz, P., AlonsoEscolano, D., Radomski, M.W., 2004. Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. *Br J Pharmacol.* 143(7):819–826.
- Kabir, Z., Connolly, G.N., Clancy, L. 2008. Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. *Ulster Med J,* 77: 31-35.
- Kawaguchi, T., Takada, M., Kubo, A., Matsumura, A., et al., 2010. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. *J Thorac Oncol.* 5(5): 620-630.
- Komite Penanggulangan Kanker Nasional, 2017. Pedoman Nasional Pelayanan Kesehatan: Kanker Paru. Kementrian Kesehatan, Jakarta.
- Khuder, S.A., 2001. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis, *Lung Cancer.* 31(2-3):139-48.
- Kravchenko, J., Berry, M., Arbeev, K., Kim-Lyerly, H., et al., 2015. Cardiovascular comorbidities and survival of lung cancer patients: medicare data-based analysis. *Lung Cancer.* 88(1):85–93.
- Krewski, D., Jerrett, M., Burnett, R.T., 2009. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality. *Res Rep Health Eff Inst.* 140: 5–114.



- Kurishima, K., Watanabe, H., Ishikawa, H., Satoh, H., Hizawa, N., 2017. Survival of patients with lung cancer and diabetes mellitus. *Molecular and Clinical Oncology*. 6(6): 907–910.
- Kusumanto, Y.H., Dam, W.A., Hospers, G.A., Meijer, C., Mulder, N.H., 2003. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. *Angiogenesis*. 6(4):283–287.
- Labelle, M., Begum, S., Hynes, R.O., 2011. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell*. 20(5):576–590.
- Laden, F., Schwartz, J., Speizer, F.E., 2006. Reduction in fine particulate air pollution and mortality: extended follow-up of the Harvard Six Cities study. *Am J Respir Crit Care Med*. 173: 667–672.
- Lee-Feldstein, A., 1986. Cumulative exposure to arsenic and its relationship to respiratory cancer among copper smelter employees. *J Occup Med*. 28(4):296-302.
- Lindemann, N.I., Cagle, P.T., Beasley, M.B., 2013. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Arch Pathol Lab Med*. 137(6): 828-860.
- Li, N., 2015. Platelets in cancer metastasis: To help the “villain” to do evil. *Int J Cancer*. 138(9): 20178-2087.
- Li, W., Ma, G., Qiang, W., Deng, Y., et al., 2017. Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis. *Oncotarget*. 8(66): 110606–110613.
- Lim, J.U., Yeo, C.D., Kang, H.S., Park, C.K., et al., 2018. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. *PLoS ONE*. 13(7):e0200341.
- Liu, Y., Steenland, K., Rong, Y., 2013. Exposure-response analysis and risk assessment for lung cancer in relationship to silica exposure: a 44-year cohort study of 34,018 workers. *Am J Epidemiol*. 178:1424- 1433.
- Lolli, C., Caffo, O., Scarpi, E., Aieta, M., et al., 2016. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. *Front Pharmacol*. 7:376.
- Loomis, D., Huang, W., Chen, G., 2014. The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: Focus on China. *Chin J Cancer*. 33(4):189–196.
- Lubin, J.H., Boice, J.D., Hornung, R.W., Edling, C., et al., 1994. Radon and lung cancer risk: a joint analysis of 11 underground miners studies. *Natl Inst Hlth, NIH Publ*. 94:3644.
- Lu, M.S., Chen, M.F., Lin, C.C., Tseng, Y.H., et al., 2017. Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity scores matching study. *Thorac Cancer*. 8:106–13.

- Machida, H., De Zoysa, M.Y., Takiuchi, T., Hom, M.S., *et al.*, 2017. Significance of monocyte counts at recurrence on survival outcome of women with endometrial cancer. *Int J Gynecol Cancer*. 27(2): 302-310.
- Madeddu, C., Mantovani, G., Gramignano, G. Muscle wasting as main evidence of energy impairment in cancer cachexia: Future therapeutic approaches. *Future Oncol*, 11:2697–710.
- Mantovani, A., Allavena, P., Sica, A., Balkwill, F., 2008. Cancer-related inflammation. *Nature*. 454: 436–444.
- Markowitz, S.B., Levin, S.M., Miller, A., Morabia, A., 2013. Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. *Am J Respir Crit Care Med*. 188(1): 90-96.
- McMillan, D.C., Watson, W.S., O'Gorman, P., Preston, T., *et al.*, 2001. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. *Nutr Cancer*, 39:210–213.
- Mellemgaard, A., Lüchtenborg, M., Iachina, M., 2015. Role of comorbidity on survival after radiotherapy and chemotherapy for nonsurgically treated lung cancer. *J Thorac Oncol*. 10: 272–279.
- Meza, R., Meernik, C., Jeon, J., Cote, M.L., 2015. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. *PLoS ONE* 10(3): e0121323.
- Miller, V.A., Riely, G.J., Zakowski, M.F., 2008. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *J Clin Oncol*. 26:1472-1478.
- Na, S.Y., Sung, J.Y., Chang, J.H, Kim, S., *et al.*, 2011. Chronic kidney disease in cancer patients: An independent predictor of cancer-specific mortality. *Am J Nephrol*. 33(2):121-130.
- Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., *et al.*, 1998. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res*. 58(16):3491–3494.
- Nakamura, H., Ando K., Shinmyo, T., Morita K., *et al.*, 2011. Female gender is an independent prognostic factor in non-small cell lung cancer: a meta-analysis. *Ann Thorac Cardiovasc Surg*. 17(5): 469-480.
- National Comprehensive Cancer Network (NCCN), 2018. Non-Small Cell Lung Cancer (Version 4.2018). [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Diakses 26 April 2018.
- Ocana, A., Nieto-Jiménez, C., Pandiella, A., Templeton, A. J., 2017. Neutrophils in cancer: prognostic role and therapeutic strategies. *Mol Cancer*. 16:137.
- O'Higgins, C.M., O'Connor, B.B., Walsh, D., Reilly, R.B., 2018. The pathophysiology of cancer-related fatigue: Current controversies. *Supportive Care in Cancer*, 26: 3353-3364.
- Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., *et al.*, 1982. Toxicity and response criteria of the eastern Cooperative oncology group. *Am J Clin Oncol*. 5:649-655
- Paik, P.K., Varghese, A.M., Sima, C.S., 2012. Response to erlotinib in patients

- with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. *Mol Cancer Ther.* 11:2535-2540.
- Paramanathan, A., Saxena, A., Morris, D.L., 2014. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. *Surg Oncol.* 23:31–39.
- Pauk, N., Kubik, A., Zattloukal, P., Krepela, E. 2005. Lung cancer in women. *Lung cancer*, 48: 1-9.
- Pesch, B., Kendzia, B., Gustavsson, P., Jockel, K.H., et al., 2012. Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies. *Int J Cancer.* 131:1210–1219.
- Petrick, J.L., Reeve, B.B., Kucharska-Newton, A.M., Foraker, R.E., et al., 2015. Functional status declines among cancer survivors: Trajectory and contributing factors. *J Geriatr Oncol*, 5: 359-367.
- Pinter, M., Trauner, M., Peck-Radosavljevic, M., 2016. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open*. 1(2): e000042.
- Poinen-Rughooputh, S., Rughooputh, M.S., Guo, Y., Rong, Y., Chen, W., 2016. Occupational exposure to silica dust and risk of lung cancer: an updated meta-analysis of epidemiological studies. *BMC Public Health*. 16:1137.
- Raaschou-Nielsen, O., Andersen, Z.J., Beelen, R., 2013. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). *Lancet Oncol.* 14: 813–822.
- Ren, Y., Dai, C., Zheng, H., Zhou, F., et al., 2016. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. *Oncotarget*, 7: 53245-53253.
- Ribas, A., 2015. Releasing the brakes on cancer immunotherapy. *N Engl J Med* 373:1490-1492.
- Riihimaki, M., Hemminki, A., Fallah, M., Thomsen, H., et al., 2014. Metastatic sites and survival in lung cancer. *Lung Cancer*. 86(1):78-84.
- Russell, P.A., Wainer, Z., Wright, G.M., Daniels, M., et al., 2011. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol.* 6:1496–1504.
- Sagerup, C.M.T., Smastuen, M., Johannessen, T.B., Helland, A., Brustugun, O.T. 2011. Sex-specific trends in lung cancer incidence and survival: A population study of 40 118 cases. *Thorax*, 66: 301-307.
- Santillan, A.A., Camargo, C.A., Colditz, G.A., 2003. A meta-analysis of asthma and risk of lung cancer (United States). *Cancer Causes Control*. 14: 327-334.
- Sekine, Y., Behnia, M., Fujisawa, T., 2002. Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. *Lung Cancer*. 37(1):95-101.

- Shah, S., Blanchette, C.M. Kowalkowski, M., Arthur, S.T., *et al.*, 2017. Survival associated with chronic obstructive pulmonary disease among elderly patients with non-small cell lung cancer, *Journal of Clinical Oncology*. 35:15\_suppl, e18107-e18107.
- Sharma, D., Brummel-Ziedins, K.E., Bouchard, B.A., Holmes, C.E., 2014. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. *J Cell Physiol*. 229(8):1005–1015.
- Shaw, A.T., Ou, S.H., Bang, Y.J., 2014. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*. 371:1963-1971.
- Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., 2009. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol*. 27:4247-4253.
- Sheng, J., Yang, Y.P., Ma, Y.X., 2016. Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs. *PLoS One*. 11: e0147226.
- Shieh, S.H., Probst, J.C., Sung, F.C., Tsai, W.C., *et al.*, 2012. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. *BMC Cancer*. 12: 174.
- Shiroyama, T., Suzuki, H., Tamiya, M., Tamiya, A., *et al.*, 2018. Clinical characteristics of liver metastasis in Nivolumab-treated patients with non-small cell lung cancer. *Anticancer research*, 38:4723-4729.
- Shoji, F., Morodomi, Y., Akamine, T., Takamori, S., *et al.*, 2016. Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer. *Lung Cancer*. 98:15–21.
- Silverman, D.T., Samanic, C.M., Lubin, J.H., 2012. The Diesel Exhaust in Miners Study: a nested case-control study of lung cancer and diesel exhaust. *J Natl Cancer Inst*. 104:855–868.
- Simmons, C.P., Koinis, F., Fallon, M.T., Fearon, K.C., *et al.*, 2015. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors. *Lung Cancer*. 88(3): 304-309.
- Smyth, M.J., Hayakawa, Y., Takeda, K., Yagita, H., 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. *Nat Rev Cancer*. 2(11):850–861.
- Steenland, K., Mannetje, A., Boffetta, P., 2001. Pooled exposure-response analyses and risk assessment for lung cancer in 10 cohorts of silica-exposed workers: An IARC multicentre study. *Cancer Causes Control* 12:773–784.
- Steenland, K., Ward, E., 2014. Silica: a lung carcinogen. *CA Cancer J Clin*. 64: 63-69.
- Tammemagi, C.M., Nesulund-Dudas, C., Simoff, M., Kvale, P., 2003. Impact of comorbidity on lung cancer survival. *Int J Cancer*. 103(6):792–802.
- Tomita, M., Ayabe, T., Maeda, R., Nakamura, K., 2018. Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer. *In Vivo*. 32(3):663-667.
- Tong, Y.S., Tan, J., Zhou, X.L., Song, Y.Q., Song, Y.J., 2017. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome

- in patients with stage III non-small cell lung cancer. *J Transl Med.* 15:221.
- Torre, L.A., Siegel, R.I., Jemal, A. 2016. Lung cancer statistics. *Adv Exp Med Biol*, 893: 1-9.
- Travis, W.D., Brambilla, E., Müller-Hermelink, H.K., Harris, C.C., 2004. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. *WHO Classification of Tumours*. IARC Press, Lyon.
- Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G., 2015. WHO Classification of Lung Tumours. *Journal of Thoracic Oncology*. 10(9): 1243-1260.
- Tsao, M.S., Marguet, S., Le-Tuuff, G., 2015. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. *J Clin Oncol.* 33(30): 3439-3446.
- Van der Meij, B.S., Schoonbeek, C.P., Smit, E.F., 2013. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: An exploratory study comparing two consensus-based frameworks. *Br J Nutr*, 109:2231–9.
- Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., Brossay, L., 2012. Targeting natural killer cells and natural killer T cells in cancer. *Nat Rev Immunol.* 12(4):239–252.
- Wang, J., Liu, Q., Yuan, S., Xie, W., et al., 2017. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. *Sci. Rep.* 7:8371.
- Wei, Y.F., Chen, J.Y., Lee, H.S., 2018. Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. *BMJ Open*. 8: e019661.
- Yang, Z., Zhang, J., Lu, Y., Xu, Q., et al., 2015. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. *Oncotarget*. 6:43090–43098.
- Yao, J.J., Zhu, F.T., Dong, J. 2019. Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area. *BMC Cancer*, 19:37.
- Yun, Y.H., Lim, M.K., Jung, K.W., Bae, J.M., et al., 2005. Relative and absolute risks of cigarette smoking on major histologic types of lung cancer in Korean men. *Cancer Epidemiol Biomarkers Prev.* 14(9):2125-2130.
- Zhang, X., Jiang, N., Wang, L., Liu, H., & He, R., 2017. Chronic obstructive pulmonary disease and risk of lung cancer: a meta-analysis of prospective cohort studies. *Oncotarget*. 8(44), 78044–78056.
- Zheng, W., Blot, W., Liao, M., 1987. Lung cancer and prior tuberculosis infection in Shanghai. *Br J Cancer*. 56: 501–505.
- Zhou, Y., Cui, Z., Zhou, X., Chen, C., et al., 2013. The presence of old pulmonary tuberculosis is an independent prognostic factor for squamous cell lung cancer survival. *J Cardiothorac Surg*. 8: 123.